The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2026 | CHARLI: denosumab plus checkpoint inhibitors in advanced melanoma
Peter Lau, MBBS, PhD, Harry Perkins Institute of Medical Research, Nedlands, Australia, discusses the final analysis of the Phase Ib/II CHARLI (NCT03161756) trial evaluating the addition of the anti-RANKL antibody denosumab to nivolumab or ipilimumab plus nivolumab in patients with treatment-naïve, unresectable stage III/IV melanoma. Both combinations showed encouraging progression-free survival, numerically exceeding historical standards, alongside high response rates. Nivolumab plus denosumab was well tolerated, whereas the triplet regimen was associated with more frequent high-grade immune-related toxicities. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
